FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Huang Dennis Karl						2. Issuer Name and Ticker or Trading Symbol Ultragenyx Pharmaceutical Inc. [ RARE ]									5. Relationship of Reporting Person(s) to Issue (Check all applicable)  Director 10% Owner				
(Last)	,	irst) X PHARMACE	(Middle)	INC.			of Earliest 2024	Trans	action (M	onth/	Day/Year)			] ;	X Officer below)	(give title See R	temark	Other (s below)	pecify
60 LEVERONI COURT				4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person						
(Street) NOVATO	O C.	A	94949											1	_	led by Mor	•	One Repor	
(City)	(S	tate)	(Zip)		Rı	Rule 10b5-1(c) Transaction Indication													
	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.										to								
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)  2. Transa Date (Month/D				Execution Date		Date,	Code (Instr.						Beneficia	es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Direct of Indirect Estr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount		(A) or (D)	Price	Transact (Instr. 3	tion(s)			(1130.4)
Common Stock 03/01/2			/2024		A		17,800(1)		A	\$ <mark>0</mark>	82,	82,515		D					
Common Stock 03/01/2			/2024		A		957(2)		A	\$ <mark>0</mark>	83,	83,472		D					
Common	Common Stock 03/01/2		/2024	2024		F		470(3)		D	\$53.69	83,002(4)			D				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transa Code (I		5. Number on of		6. Date Exercisa Expiration Date (Month/Day/Year		able and 7. T of S unc		7. Title and Am of Securities Underlying Derivative Sect (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e O s Fo ally D	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(A) (D) Exe				iration e Title		Amount or Number of Shares					

## **Explanation of Responses:**

\$53.69

1. Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date

(5)

03/01/2034

2. Represents shares of common stock which previously granted performance stock units were converted on March 1, 2024 upon certification of the performance metric.

31,400

- 3. Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.
- 4. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

A

5. On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.

## Remarks:

Stock Option (Right to

EVP, Chief Technical Operations Officer

/s/ Karah Parschauer, attorneyin-fact

31,400

Stock

\$0

03/05/2024

31,400

D

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

03/01/2024

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.